primary IgA nephropathy

Novartis' Complement Inhibitor Fabhalta Approved for IgAN
Contract Pharma
Mon, 08/12/24 - 05:52 pm
FDA
Novartis
Fabhalta
primary IgA nephropathy
FDA sets September review date for Calliditas’ rare kidney disease drug
Pharmaforum
Thu, 04/29/21 - 10:26 am
Calliditas
Nefecon
primary IgA nephropathy
kidney disease
FDA